Holen Sie sich die Stockscreener-App
2.42
1.63%
-0.04
Handel nachbörslich:
2.46
0.04
+1.65%
Schlusskurs vom Vortag:
$2.46
Offen:
$2.43
24-Stunden-Volumen:
1.47M
Relative Volume:
1.05
Marktkapitalisierung:
$686.48M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-125.04M
KGV:
-2.9512
EPS:
-0.82
Netto-Cashflow:
$-122.99M
1W Leistung:
+1.68%
1M Leistung:
+11.01%
6M Leistung:
+65.75%
1J Leistung:
-6.56%
1-Tages-Spanne:
$2.39
$2.505
1-Wochen-Bereich:
$2.34
$2.54
52-Wochen-Spanne:
$1.01
$3.305
Erasca Inc Stock (ERAS) Company Profile
Firmenname
Erasca Inc
Sektor
Branche
Telefon
(858) 465-6511
Adresse
3115 MERRYFIELD ROW, SAN DIEGO
Vergleichen Sie ERAS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
2.42 | 697.83M | 0 | -125.04M | -122.99M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | -52.09M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-16 | Eingeleitet | Stifel | Buy |
| 2025-09-03 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-08-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-26 | Eingeleitet | Raymond James | Outperform |
| 2024-11-18 | Eingeleitet | Jefferies | Buy |
| 2024-03-11 | Eingeleitet | CapitalOne | Overweight |
| 2024-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-10-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-03-30 | Eingeleitet | Mizuho | Buy |
| 2023-02-24 | Eingeleitet | Goldman | Buy |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
Alle ansehen
Erasca Inc Aktie (ERAS) Neueste Nachrichten
Full technical analysis of Erasca Inc. stockQuarterly Earnings Report & Weekly Market Pulse Updates - newser.com
Using fundamentals and technicals on Erasca Inc.July 2025 Spike Watch & Low Risk High Win Rate Stock Picks - newser.com
Best data tools to analyze Erasca Inc. stockTrade Analysis Report & Expert-Curated Trade Recommendations - newser.com
How to forecast Erasca Inc. trends using time series2025 Trading Recap & Fast Gaining Stock Strategy Reports - newser.com
Why Erasca Inc. stock remains a top recommendationWeekly Investment Recap & Advanced Technical Signal Analysis - newser.com
Analyzing drawdowns of Erasca Inc. with statistical toolsGap Up & Safe Entry Trade Signal Reports - newser.com
Is Erasca Inc. stock oversold or undervaluedAnalyst Upgrade & Momentum Based Trading Signals - newser.com
Analyzing net buyer seller activity in Erasca Inc.July 2025 Fed Impact & Low Drawdown Investment Strategies - newser.com
Heatmap analysis for Erasca Inc. and competitorsWeekly Stock Report & Risk Managed Investment Strategies - newser.com
Risk vs reward if holding onto Erasca Inc.Weekly Trade Review & Verified Chart Pattern Trade Signals - newser.com
Is Erasca Inc. stock affected by interest rate hikesPrice Action & Weekly High Return Forecasts - newser.com
Understanding Erasca Inc.’s price movementWatch List & Stepwise Trade Signal Guides - newser.com
Is Erasca Inc. still worth holding after the dipJuly 2025 Catalysts & Low Risk Growth Stock Ideas - newser.com
Is Erasca Inc. stock poised for growthEarnings Growth Summary & Entry and Exit Point Strategies - newser.com
Can Erasca Inc. stock deliver sustainable ROEQuarterly Market Summary & Risk Controlled Daily Trade Plans - newser.com
Erasca, Inc. Advances in Cancer Treatment with ERAS-0015 Study - TipRanks
Will Erasca Inc. stock maintain growth storyGold Moves & Long-Term Growth Portfolio Plans - newser.com
What analysts say about Erasca Inc stockTrade Execution Strategies & Rapid Profit Growth - earlytimes.in
How Erasca Inc. stock performs in weak economyQuarterly Growth Report & Long-Term Capital Growth Ideas - newser.com
Portfolio Update: Will Erasca Inc. stock maintain growth storyJuly 2025 Rallies & Smart Allocation Stock Reports - Fundação Cultural do Pará
Erasca, Inc. Advances with Promising Phase 1 Study on ERAS-4001 - TipRanks
Finanzdaten der Erasca Inc-Aktie (ERAS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.62%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):